FH Europe joins the World Heart Federation and EURORDIS
We are pleased to announce very positive and important updates.
On April 17, 2020, FH Europe had been welcomed as an official member to the World Heart Federation – powerful global community of organizations dedicated to the treatment, prevention and control of cardiovascular disease. Also, the same day, we have officially joined EURORDIS – European Rare Diseases Organisation. With over 900 direct member organisations, EURORDIS is recognised and listened to as the European organisation specialised in the needs of patients with rare diseases.
These two important collaborations demonstrate our Network’s commitment to our mission.
The advancement of health and the prevention of early cardiovascular disease, particularly but not exclusively by:
- the provision and sharing of information about dyslipidaemia, including familial hypercholesterolaemia (FH), its rare form HoFH, and related conditions Lp(a) as well as FCS; and
- the promotion of research into the causes, diagnosis and treatment and the dissemination of the useful results of such research.
FH Europe is supported by an educational grant from Amgen Limited, Sanofi, Regeneron, Akcea Therapeutics Inc. and Amryt